Overview
Evonetix develops semiconductor chip-based DNA synthesis technology that enables rapid, high-fidelity gene-length DNA production on a benchtop platform. The company's proprietary approach integrates physics and biology to synthesize DNA at thousands of independently controlled reaction sites with built-in error correction, potentially delivering gene synthesis in three days with 10-fold productivity improvements. This technology accelerates the design-build-test cycle for vaccines, antibodies, proteins, and other synthetic biological solutions used in drug discovery and development.
Frequently asked questions
- What is Evonetix's core technology and how does it differ from conventional DNA synthesis?
- Evonetix develops third-generation DNA synthesis using silicon chips made through MEMS processing that control synthesis at thousands of independently controlled reaction sites. Unlike conventional sequential chemical synthesis, their platform synthesizes DNA in parallel across chip 'pixels' and includes integrated on-chip assembly with thermal error correction that removes imperfect DNA sequences, providing accuracy several orders of magnitude better than traditional methods.
- What are the key performance benefits for R&D and pharmaceutical applications?
- Evonetix's platform can prepare gene-length DNA in three days at the benchtop, accelerating the design-build-test cycle from months to days. The technology offers up to 10-fold productivity increases in gene delivery and enables researchers to synthesize accurate, long DNA sequences with built-in error removal, supporting faster development of vaccines, antibodies, proteins, and other therapeutic candidates.
- What is the form factor and accessibility of Evonetix's solution?
- Evonetix is developing a desktop DNA synthesis device called the Evaleo series that integrates semiconductor technology with thermal control and microfluidic processing. The platform is designed as a plug-and-play benchtop device to place DNA synthesis capabilities directly in research laboratories, making high-fidelity gene synthesis accessible to individual researchers rather than requiring centralized synthesis facilities.
- What stage of development is Evonetix at and what partnerships support commercialization?
- Evonetix has shipped early samples of semiconductor-synthesized DNA to laboratory users and is in active product development. The company has strategic partnerships with Analog Devices for ASIC design and thermal control electronics, and collaborates with imec on scaling chip-based production. In May 2023, Evonetix delivered its first chip-synthesized DNA to the University of Cambridge, marking a key milestone in platform development.